Latest period
$871.00K
YoY change
0.0%
5Y CAGR
+0.2%
Peak year (2016)
$16.40M
Latest annual
$1.00M
Total Debt history chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: $1.00M
Total Debt growth chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: 0.0%
Total Debt history table for SELLAS Life Sciences Group (SLS) from 2006 to 2025
| 2025 | $1.00M | 0.0% | $0.00 | ||
| 2024 | $1.00M | +10.5% | +$95.00K | ||
| 2023 | $906.00K | -4.1% | −$39.00K | ||
| 2022 | $945.00K | +17.0% | +$137.00K | ||
| 2021 | $808.00K | -18.5% | −$183.00K | ||
| 2020 | $991.00K | +356.7% | +$774.00K | ||
| 2019 | $217.00K | — | +$217.00K | ||
| 2018 | $0.00 | -100.0% | −$10.99M | ||
| 2017 | $10.99M | -33.0% | −$5.41M | ||
| 2016 | $16.40M | +246.0% | +$11.66M | ||
| 2015 | $4.74M | -43.6% | −$3.66M | ||
| 2014 | $8.40M | -15.3% | −$1.52M | ||
| 2013 | $9.92M | +17310.5% | +$9.87M | ||
| 2012 | $57.00K | -89.9% | −$510.00K | ||
| 2011 | $567.00K | +698.6% | +$496.00K | ||
| 2010 | $71.00K | -19.3% | −$17.00K | ||
| 2009 | $88.00K | +319.0% | +$67.00K | ||
| 2008 | $21.00K | — | +$21.00K | ||
| 2007 | $0.00 | — | $0.00 | ||
| 2006 | $0.00 | — | — |
- 2025$1.00M0.0%
- 2024$1.00M+10.5%
- 2023$906.00K-4.1%
- 2022$945.00K+17.0%
- 2021$808.00K-18.5%
- 2020$991.00K+356.7%
- 2019$217.00K—
- 2018$0.00-100.0%
- 2017$10.99M-33.0%
- 2016$16.40M+246.0%
- 2015$4.74M-43.6%
- 2014$8.40M-15.3%
- 2013$9.92M+17310.5%
- 2012$57.00K-89.9%
- 2011$567.00K+698.6%
- 2010$71.00K-19.3%
- 2009$88.00K+319.0%
- 2008$21.00K—
- 2007$0.00—
- 2006$0.00—
Total Debt values are taken from SELLAS Life Sciences Group's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Debt at SELLAS Life Sciences Group (SLS)
According to SELLAS Life Sciences Group's latest reported financial statements, the company's latest reported total debt is $871.00K. Total debt is the sum of short-term and long-term interest-bearing borrowings on the balance sheet (notes, bonds, term loans, lease liabilities). Useful for leverage and refinancing risk — compare with cash on hand for net leverage, and total liabilities for the broader obligations picture.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of SELLAS Life Sciences Group (SLS) total debt is $1.00M – edged up 0.0% year-over-year.
Through 2020–2025 (5 years), SELLAS Life Sciences Group total debt delivered a +0.2% annualised rate; with mixed annual results across the window.
2016 marks the peak total debt at $16.40M, with the historical low of $0.00 recorded in 2006.
SELLAS Life Sciences Group Total Debt by Year
SELLAS Life Sciences Group Total Debt 2025: $1.00M
2025's total debt for SELLAS Life Sciences Group came in at $1.00M, edged up 0.0% from 2024.
SELLAS Life Sciences Group Total Debt 2024: $1.00M
SELLAS Life Sciences Group posted total debt of $1.00M in 2024, grew 10.5% from 2023.
SELLAS Life Sciences Group Total Debt 2023: $906.00K
In 2023, SELLAS Life Sciences Group reported total debt of $906.00K, edged down 4.1% below 2022.
SELLAS Life Sciences Group Total Debt 2022: $945.00K
SELLAS Life Sciences Group total debt in 2022 was $945.00K, grew 17.0% from 2021.
SELLAS Life Sciences Group Total Debt 2021: $808.00K
SELLAS Life Sciences Group total debt in 2021 was $808.00K.
See more financial history for SELLAS Life Sciences Group (SLS).
Sector peers by Total Debt
Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by their latest total debt
| $78.39B | |
| $69.07B | |
| $54.60B | |
| $50.53B | |
| $47.93B | |
| $42.50B | |
| $29.70B | |
| $20.59B |
- $78.39B
- $69.07B
- $54.60B
- $50.53B
- $47.93B
- $42.50B
- $29.70B
- $20.59B
Frequently asked questions
SELLAS Life Sciences Group (SLS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation